Vanda Secures EMA Positive Opinion For Imsidolimab In Generalized Pustular Psoriasis

Source and reference

source on Google Add Now Vanda Pharmaceuticals Inc. ( VNDA ) announced that the European Medicines Agency's Committee for Orphan Medicinal Products has issued a positive opinion recommending orphan drug designation for Imsidolimab, its investigational monoclonal antibody, for the treatment of generalized pustular psoriasis. Understanding GPP Generalized pustular psoriasis (GPP) is a severe, chronic, and potentially life-threatening inflammatory skin disease, genetically and clinically distinct from plaque psoriasis. It is driven by dysregulation in the interleukin-36 (IL-36) signaling pathway and is marked by widespread pustular eruptions, systemic inflammation, and serious complications that can lead to increased mortality. Imsidolimab works by inhibiting IL-36 receptor signaling addressing deficiencies in the natural IL-36 receptor antagonist often seen in patients with GPP. EMA's...